AKT2 and neoplasm: We next sought to test if AKT2 knockout impaired tumor initiation when compared to AKT1 and AKT3 deletion, as our CRISPR-edited WM1799 cells exhibited more robust AKT2 deletion compared to the inducible knockdown lines, which did not impact tumor initiation.